Latest Pharmaceuticals News

Bioxyne Limited posted a record $21.3 million revenue in Q3 FY26, driven by strong demand for medicinal cannabis and psychedelics. The company secured a manufacturing agreement with Aurora Cannabis and initial orders for GMP psilocybin capsules, reaffirming FY26 guidance.

Nexalis Therapeutics has advanced its IRX-211 program by screening the first patient in a pivotal Phase 2 trial for Breakthrough Cancer Pain, aiming to address a significant unmet need in oncology supportive care.

Botanix Pharmaceuticals has agreed to terms with Piramal to establish an alternate supplier for the active ingredient in Sofdra, aiming to reduce costs by up to 40% and strengthen its supply chain.

Wellnex Life has extended its licensing and supply agreement with Haleon UK for soft gel liquid paracetamol products until March 2027, reinforcing its position in the global analgesics market.

Algorae Pharmaceuticals has reached a key regulatory milestone as the TGA accepts its initial registration dossier, paving the way for potential commercialisation of its generic medicines in Australia and New Zealand.

Firebrick Pharma has successfully secured $1.5 million through a strategic placement, positioning itself to accelerate business development and launch new products in key markets.

Botanix Pharmaceuticals has successfully renegotiated its API supply agreement, deferring significant purchases to later years and strengthening its financial position ahead of Sofdra's market rollout.

Algorae Pharmaceuticals has launched a second collaboration with Peter MacCallum Cancer Centre to validate AI-predicted drug combinations across multiple cancer types, aiming to accelerate its drug development pipeline.

Firebrick Pharma has secured its first regulatory approval for Nasodine Nasal Spray in Indonesia, paving the way for entry into Southeast Asia’s largest market. This milestone marks a significant step in the company’s international expansion strategy.

Eve Health Group is advancing its proprietary reformulation platform with two fast-onset products launched under Australia's SAS-B pathway, targeting large underserved markets in women's and men's health. The company’s capital-light, partner-led model aims for rapid revenue growth post-ARTG registration.

Recce Pharmaceuticals has expanded its intellectual property footprint with a newly granted patent in Brazil, protecting its innovative synthetic anti-infectives against a broad range of infections. This milestone strengthens Recce’s position in one of South America’s largest antibiotic markets.

Amplia Therapeutics reports a remarkable 7.8% complete response rate and improved survival in its ACCENT pancreatic cancer trial, positioning narmafotinib as a promising new treatment option.